The cytotoxicity of methyl protoneogracillin (NSC-698793) and gracillin (NSC-698787), two steroidal saponins from the rhizomes of Dioscorea collettii var. hypoglauca, against human cancer cells in vitro

Phytotherapy Research

Volumn 17, Issue 6, 2003, Pages 620-626

  Hu, Ke ^a   Yao, Xinsheng ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytotoxicity; Dioscorea collettii var. hypoglauca; Dioscoreaceae; Gracillin; Methyl protoneogracillin; NSC 698787; NSC 698793

Indexed keywords

FUROSTANOL; GRACILLIN; METHYLPROTOGRACILLIN; METHYLPROTONEOGRACILLIN; NSC 698787; NSC 698792; NSC 698793; PLANT EXTRACT; SAPONIN; SPIROSTANOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; COMPUTER PROGRAM; CYTOTOXICITY; DATA BASE; DIOSCOREA COLLETTII; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LC 50; LEUKEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PROSTATE CANCER; RHIZOME; STRUCTURE ACTIVITY RELATION; YAM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COLONIC NEOPLASMS; DIOSCOREA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY NEOPLASMS; LETHAL DOSE 50; LEUKEMIA; MALE; MELANOMA; MICE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; PROSTATIC NEOPLASMS; SAPONINS; SPIROSTANS; STEROIDS; TUMOR CELLS, CULTURED;

DIOSCOREA; DIOSCOREA COLLETTII; DIOSCOREACEAE; MUS MUSCULUS;

EID: 0038802394     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1211     Document Type: Article

References (20)

1. Alley MC, Scudiero DA, Monks A, et al. 1998. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601.
2. Bates SE, Fojo AT, Weinstein JN, et al. 1995. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 121: 495-500.
3. Boyd MR. 1989. Status of the NCI preclinical antitumor drug discovery screen. In Cancer: Principles and Practice of Oncology Updates, de Vita VT Jr, Hellman S, Rosenberg SA (eds). Lippincott Williams & Wilkins: Philadelphia; 1-12.
4. Boyd MR, Paull KD. 1995. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109.
5. Grever MR, Schepartz SA, Chabner BA. 1992. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19: 622-638.
6. Hollingshead MG, Alley MC, Camalier RF et al. 1995. In vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141.
7. Hu K, Dong A, Yao X et al. 1996. Antineoplastic agents; I. Three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Planta Med 62: 573-575.
8. Hu K, Dong A, Yao X et al. 1997a. Antineoplastic agents; II. Four furostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Planta Med 63: 161-165.
9. Hu K, Dong A, Yao X et al. 1997b. A furostanol glycoside from rhizomes of Dioscorea collettii var. hypoglauca. Phytochemistry 44: 1339-1342.
10. Hu K, Kobayashi H, Dong A et al. 1998. A new pregnane glycoside from Dioscorea collettii var. hypoglauca. Chin Chem Lett 9: 739-742.
11. Hu K, Yao X, Dong A et al. 1999. A new pregnane glycoside from Dioscorea collettii var. hypoglauca. J Nat Prod 62: 299-301.
12. Hu K, Yao X. 2001. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel. Anticancer Drugs 12: 541-547.
13. Kobayashi H, Namikoshi M, Yoshimoto T, Yokochi T. 1996. A screening method for antimitotic and antifungal substances using conidia of Pyricularia oryzae, modification and application to tropical marine fungi. J Antibiotics 49: 873-879.
14. Monks A, Scudiero D, Skehan P et al. 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
15. Monks A, Scudiero DA, Johnson GS et al. 1997. The NCI anticancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 12: 533-541.
16. Paull KD, Shoemaker RH, Hodes L et al. 1989. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092.
17. Rubinstein LV, Shoemaker RH, Paull KD et al. 1990. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118.
18. Skehan P, Storeng R, Scudiero D et al. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
19. Weinstein JN, Kohn KW, Grever MR et al. 1992. Neural computing in cancer drug development: predicting mechanism of action. Science 258: 447-451.
20. Weinstein JN, Myers TG, O'Connor PM et al. 1997. An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349.